Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) and HCW Biologics (NASDAQ:HCWB – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.
Analyst Ratings
This is a summary of recent ratings for Eledon Pharmaceuticals and HCW Biologics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eledon Pharmaceuticals | 1 | 1 | 3 | 0 | 2.40 |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
Eledon Pharmaceuticals currently has a consensus price target of $9.67, suggesting a potential upside of 161.97%. HCW Biologics has a consensus price target of $30.00, suggesting a potential upside of 779.77%. Given HCW Biologics’ higher possible upside, analysts clearly believe HCW Biologics is more favorable than Eledon Pharmaceuticals.
Insider and Institutional Ownership
Profitability
This table compares Eledon Pharmaceuticals and HCW Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eledon Pharmaceuticals | N/A | -116.97% | -41.91% |
| HCW Biologics | -34.73% | -486.87% | -29.19% |
Volatility and Risk
Eledon Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500.
Earnings and Valuation
This table compares Eledon Pharmaceuticals and HCW Biologics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eledon Pharmaceuticals | N/A | N/A | -$45.62 million | ($0.77) | -4.79 |
| HCW Biologics | $50,000.00 | 109.12 | -$7.96 million | ($56.75) | -0.06 |
HCW Biologics has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Summary
Eledon Pharmaceuticals beats HCW Biologics on 7 of the 13 factors compared between the two stocks.
About Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
